These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 789041

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Slawiński M, Czarnecka H.
    Fortschr Med; 1989 Jul 10; 107(20):450-2. PubMed ID: 2767596
    [Abstract] [Full Text] [Related]

  • 23. WHO clofibrate trial.
    Castle WM.
    N Z Med J; 1981 Jan 14; 93(675):23. PubMed ID: 7010242
    [No Abstract] [Full Text] [Related]

  • 24. [Etofibrate lowers the atherosclerosis index].
    Mertz DP, Suermann I, Göhmann E.
    Med Klin; 1981 Mar 13; 76(6):166-8. PubMed ID: 7231329
    [No Abstract] [Full Text] [Related]

  • 25. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR, Chasseaud LF, Taylor T, Schatton W.
    Arzneimittelforschung; 1985 Mar 13; 35(2):489-92. PubMed ID: 4039571
    [Abstract] [Full Text] [Related]

  • 26. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M, Varsányl M, Jovanovich N, Romics L, Gerö S.
    Allergol Immunopathol (Madr); 1990 Mar 13; 18(2):95-9. PubMed ID: 2371944
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE, Kellett DN.
    Arzneimittelforschung; 1980 Mar 13; 30(11b):2035-7. PubMed ID: 7194055
    [Abstract] [Full Text] [Related]

  • 29. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Mar 13; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990 Mar 13; 85():1-15. PubMed ID: 2338325
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P.
    MMW Munch Med Wochenschr; 1980 Jan 18; 122(3):95-8. PubMed ID: 6767931
    [Abstract] [Full Text] [Related]

  • 34. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W, Schultz A.
    Arzneimittelforschung; 1974 Dec 18; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Rheumatology and the pharmaceutical industry.
    Bird HA.
    J Rheumatol; 1983 Aug 18; 10(4):663-4. PubMed ID: 6352938
    [No Abstract] [Full Text] [Related]

  • 39. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W, Holm E.
    Fortschr Med; 1986 Apr 03; 104(13):280-2. PubMed ID: 3699655
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.